Literature DB >> 15763182

Analysis of mammalian scrapie protein by novel monoclonal antibodies recognizing distinct prion protein glycoforms: an immunoblot and immunohistochemical study at the light and electron microscopic levels.

Andrea Matucci1, Gianluigi Zanusso, Matteo Gelati, Alessia Farinazzo, Michele Fiorini, Sergio Ferrari, Giancarlo Andrighetto, Tiziana Cestari, Maria Caramelli, Alessandro Negro, Michela Morbin, Roberto Chiesa, Salvatore Monaco, Giuseppe Tridente.   

Abstract

The availability of specific monoclonal antibodies (mAbs) recognizing the aberrant form (PrP(Sc)) of the cellular prion protein (PrP(C)) in different mammalian species is important for molecular diagnostics, PrP(Sc) typing and future immunotherapy. We obtained a panel of anti-PrP monoclonal antibodies in PrP(0/0) knock-out mice immunized with recombinant human PrP(23-231). Two mAbs, recognizing PrP epitopes in the alpha-helix 1 (mAb SA65) and alpha-helix 2 (mAb SA21) regions, immunoreacted with PrP(C) and PrP(Sc) and its proteolytic product, PrP27-30, from human, murine, bovine, caprine and ovine brains by Western blot. Remarkably, mAb SA21 recognized unglycosylated and monoglycosylated PrP with the second site occupied by glycan moieties, but not monoglycosylated PrP with the first consensus site occupied or highly glycosylated species. Immunoblots with mAb SA21 disclosed that PrP glycosylated at the second site accounted for the slower migrating form of the customary monoglycosylated PrP doublet. mAb SA65 immunolabelled all PrP glycoforms by Western blot and was highly efficient in detecting tissue PrP by immunohistochemistry in light microscopy and in immunoelectron microscopy. These novel anti-PrP mAbs provide tools to investigate the subcellular site of PrP deposition in mammalian prion diseases and may also contribute to assess the role of different PrP glycoforms in human and animal prion diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15763182     DOI: 10.1016/j.brainresbull.2004.12.008

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  5 in total

1.  Mutant prion protein expression is associated with an alteration of the Rab GDP dissociation inhibitor alpha (GDI)/Rab11 pathway.

Authors:  Tania Massignan; Emiliano Biasini; Eliana Lauranzano; Pietro Veglianese; Mauro Pignataro; Luana Fioriti; David A Harris; Mario Salmona; Roberto Chiesa; Valentina Bonetto
Journal:  Mol Cell Proteomics       Date:  2009-12-07       Impact factor: 5.911

Review 2.  The consequences of pathogenic mutations to the human prion protein.

Authors:  Marc W van der Kamp; Valerie Daggett
Journal:  Protein Eng Des Sel       Date:  2009-07-14       Impact factor: 1.650

3.  A novel, drug-based, cellular assay for the activity of neurotoxic mutants of the prion protein.

Authors:  Tania Massignan; Richard S Stewart; Emiliano Biasini; Isaac H Solomon; Valentina Bonetto; Roberto Chiesa; David A Harris
Journal:  J Biol Chem       Date:  2009-11-24       Impact factor: 5.157

4.  Generation of genetic engineering monoclonal antibodies against prion protein.

Authors:  Yin-Xia Huang; Jun Han; Chen-Fang Dong; Li Sun; Chen Gao; Xiao-Fan Wang; Lu Han; Wei Zhou; Bao-Yun Zhang; Hui-Ying Jiang; Mi-Fang Liang; Xiao-Ping Dong
Journal:  Med Microbiol Immunol       Date:  2007-05-08       Impact factor: 3.402

5.  Adult-onset Alexander disease, associated with a mutation in an alternative GFAP transcript, may be phenotypically modulated by a non-neutral HDAC6 variant.

Authors:  Laura Melchionda; Mingyan Fang; Hairong Wang; Valeria Fugnanesi; Michela Morbin; Xuanzhu Liu; Wenyan Li; Isabella Ceccherini; Laura Farina; Mario Savoiardo; Pio D'Adamo; Jianguo Zhang; Alfredo Costa; Sabrina Ravaglia; Daniele Ghezzi; Massimo Zeviani
Journal:  Orphanet J Rare Dis       Date:  2013-05-01       Impact factor: 4.123

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.